Pfizer (PFE) Income Statement

Click line-items for a historical chart and %

Revenues
Costs and expenses:
Cost of sales
Selling, informational and administrative expenses	3.56B
Research and development expenses	1.88B
Amortization of intangible assets
Acquisition-related in-process research and development charges
Restructuring charges and certain acquisition-related costs	531M
Other deductions--net
Income from continuing operations before provision for taxes on income	1.6B
Provision for taxes on income	284M
Income from continuing operations	1.32B
Discontinued operations:
Income from operations--net of tax
Gain on sale of discontinued operations--net of tax
Discontinued operations--net of tax	0
Net income before allocation to noncontrolling interests	1.32B
Less: Net income attributable to noncontrolling interests	0
Net income attributable to Pfizer Inc.	1.32B
Earnings per share--basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders	0.22
Discontinued operations--net of tax (in dollars per share)	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	0.22
Earnings per share--diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	0.22
Discontinued operations--net of tax (in dollars per share)	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	0.21
Weighted-average shares used to calculate earnings per common share:
Basic (in shares)	6.07B
Diluted (in shares)	6.14B
Cash dividends paid per common share (in dollars per share)	0.3

Entities mentioned with PFE